C9orf72 and amyotrophic lateral sclerosis: Although progress towards treating SOD1 pathogenic variants is being made (Miller et al., 2022), the, so far, less successful gene therapy approach for C9orf72-related ALS (Boros et al., 2022) highlights the urgent need for preclinical models for the C9orf72 variant.